for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease.

Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013.

BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in collaboration with Hospira.